Antiviral substrate and mask

Abstract

To provide an antiviral base material having the quality as an antiviral base material, and a mask.SOLUTION: There is provided an antiviral base material 20 having an antiviral property, which comprises a first base material 21 made of a paper material and an antiviral layer 22 formed by applying a tea leaf extract extracted from tea leaves to the first base material 21. The coating amount of the tea leaf extract in the antiviral layer 22 is set to 0.1 g / m2 or more. The tea leaf extract includes catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate, and theaflavin-3, 3'-digallate.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] The present invention relates to an antiviral substrate and a mask. [Background technology]

[0002] Conventionally, as one substrate having antiviral properties, a substrate has been proposed which includes a sheet body made of a nonwoven fabric coated with catechin, an adhesive layer provided on the surface of the sheet body, and a release sheet removably attached to the adhesive surface of the adhesive layer (see, for example, Patent Document 1). [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Utility model registration No. 3227491 Summary of the Invention [Problem to be solved by the invention]

[0004] Here, in the above-mentioned conventional substrate, although catechin is applied to the sheet body, the details of the application are unknown, and therefore if the amount of catechin applied is insufficient, it may be difficult to obtain the desired antiviral properties. Therefore, there is room for improvement from the viewpoint of ensuring the quality of the substrate (specifically, quality related to antiviral properties).

[0005] The present invention is intended to solve the problems in the conventional technology described above, and has an object to provide an antiviral substrate and a mask that make it possible to ensure the quality of the antiviral substrate. [Means for solving the problem]

[0006] In order to solve the above problems and achieve the object, the antiviral substrate according to claim 1 is an antiviral substrate having antiviral properties, comprising a first substrate made of a paper material or a cloth material; an antiviral layer provided on the first substrate, the antiviral layer containing a substance including catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate, and theaflavin-3,3'-digallate;An antiviral layer; and a plurality of second substrates made of paper and / or cloth, the plurality of second substrates not having the antiviral layer, of, 0.2g / m 2 From 0.4 g / m 2 year, The multiple second substrates are arranged in a stacked manner, and the first substrates are arranged between the second substrates so that the first substrates are not exposed from the outside, and the multiple second substrates include an outer second substrate located on one side of the first substrate in the stacking direction, an inner second substrate located on the other side of the first substrate in the stacking direction, and an intermediate second substrate located between the first substrate and the inner second substrate, and the mesh size of at least one of the inner second substrate or the intermediate second substrate is smaller than the mesh size of the outer second substrate, and the mesh size of the first substrate is the same as the mesh size of the intermediate second substrate.

[0007] The antiviral substrate according to claim 2 is the antiviral substrate according to claim 1, material Among the components, catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate, and theaflavin-3,3'-digallate are included. Amount of ingredients of, The amount of the substance contained in the antiviral layer It was about half of that.

[0008] The method according to claim 3 mask teeth, The mask body comprises the antiviral substrate according to claim 1 or 2. Effect of the Invention

[0012] According to the antiviral substrate of claim 1, an antiviral layer is provided by applying a tea leaf extract extracted from tea leaves to a first substrate, and the amount of the tea leaf extract applied to the antiviral layer is set to: 0.2g / m 2 As described above, it is possible to have a desired antiviral property, and ensure the quality of the antiviral base material (specifically, the quality related to the antiviral property). Furthermore, since the tea leaf extract contains catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate, and theaflavin-3,3'-digallate, it is possible to reliably have the desired antiviral properties, making it easier to ensure the quality of the antiviral base material. Furthermore, multiple second substrates are provided in a layered configuration, and the first substrates are provided between the second substrates so that the first substrates are not exposed from the outside. This makes it possible to avoid exposure of the first substrate from the outside, prevent the design of the antiviral substrate from being reduced by the first substrate, and enhance the protective properties of the first substrate. Furthermore, the mesh size of at least one of the multiple second substrates located on one side of the first substrate in the stacking direction is made smaller than the mesh size of the second substrate located on the other side of the first substrate in the stacking direction. This makes it more difficult for foreign matter and / or viruses to pass through compared to when the mesh sizes of the multiple second substrates are all the same, thereby improving the filtering function.

[0013] Claim 3 According to the antiviral substrate described in Since the mask body is made of the antiviral substrate according to claim 1 or 2, the quality of the mask body can be ensured by the quality of the antiviral substrate, and the manufacturability of the mask can be improved. [Brief description of the drawings]

[0018] [Figure 1] 1A and 1B are diagrams conceptually showing a mask according to an embodiment of the present invention, where FIG. 1A is a perspective view and FIG. [Diagram 2] FIG. 2 is a diagram showing a first base material, where (a) is a front view, (b) is a rear view, and (c) is a plan view. [Diagram 3] FIG. 1 is a diagram showing the test results of a first antiviral confirmation test. [Figure 4] FIG. 13 is a diagram showing the test results of a second antiviral confirmation test. [Diagram 5] FIG. 13 is a diagram showing the test results of the third antiviral confirmation test. [Figure 6] FIG. 13 is a diagram showing the test results of the fourth antiviral confirmation test. [Figure 7] FIG. 13 is a diagram showing the test results of the fifth antiviral confirmation test. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Hereinafter, the embodiments of the antiviral substrate and mask according to the present invention will be described in detail with reference to the accompanying drawings. First, [I] the basic concept of the embodiment will be described, then [II] the specific content of the embodiment will be described, and finally, [III] modified examples of the embodiment will be described. However, the present invention is not limited to the embodiment.

[0020] [I] Basic Concept of the Embodiment First, a basic concept of the embodiment will be described. The embodiment generally relates to an antiviral substrate having antiviral properties and a mask including the antiviral substrate.

[0021] As used herein, "antiviral" refers to the ability to inactivate viruses.

[0022] The "substrate" is a member for constituting the components of a product, and in the embodiment, it is described as a member for constituting the components of a mask (specifically, the mask body described below). However, it is not limited to this, and may be a member for constituting the components of paper products other than masks (for example, paper diapers, tissue paper, toilet paper, packaging, wallpaper, printed paper, etc.) and / or cloth products (for example, cloth diapers, handkerchiefs, towels, clothes, cloth bags, etc.).

[0023] [II] Specific Contents of the Embodiments Next, the specific contents of the embodiment will be described.

[0024] (composition) First, the configuration of the mask according to the embodiment will be described.

[0025] In the following description, the X direction in FIG. 1 is referred to as the left-right direction of the mask (based on the direction as seen by a wearer not shown, with the -X direction being the right direction of the mask and the +X direction being the left direction of the mask), the Y direction in FIG. 1 is referred to as the front-to-back direction of the mask (the +Y direction is the front direction of the mask, and the -Y direction is the rear direction of the mask), and the Z direction in FIG. 1 is referred to as the up-down direction of the mask (the +Z direction is the top direction of the mask, and the -Z direction is the bottom direction of the mask).

[0026] The mask 1 is for covering the mouth and nose of a wearer, and includes a mask body 10, a pleated portion 30, a nose fitter portion 40, and an ear-side detachable portion 50, as shown in FIG.

[0027] (Configuration - Mask body) First, the configuration of the mask body 10 will be described.

[0028] The mask body 10 is the basic structure of the mask 1, and is provided at a position that can cover substantially the entire area from the wearer's nose to the chin when the wearer is wearing the mask 1 (hereinafter referred to as "worn state"). The mask body 10 is made of an antiviral substrate 20 having antiviral properties, and specifically includes a first substrate 21, an antiviral layer 22, an outer second substrate 23, an inner second substrate 24, and an intermediate second substrate 25, as shown in FIG.

[0029] The above-mentioned "outer second substrate 23", "inner second substrate 24", and "middle second substrate 25" correspond to "multiple second substrates" in the claims. In the following, among the surfaces of the mask body 10 (specifically, the first substrate 21, the outer second substrate 23, the inner second substrate 24, and the middle second substrate 25), the surface 11 facing the wearer's skin is referred to as the "mask inner surface 11", and the surface 12 opposite to the wearer's skin is referred to as the "mask outer surface 12".

[0030] (Configuration - Mask body - First base material) The first base material 21 is a part of the basic structure of the mask body 10, and is formed in a substantially sheet-like shape as shown in FIGS.

[0031] The specific shape and size of this first base material 21 are arbitrary, but in this embodiment they are set as follows.

[0032] That is, the front shape of the first base material 21 is set to be substantially quadrangular (specifically, substantially rectangular). However, it is not limited to this, and may be set to be, for example, substantially square, substantially trapezoidal, or substantially elliptical.

[0033] The length of the first base material 21 in the left-right direction is set to be approximately the same as the length of the mask body 10 in the left-right direction, and may be set to, for example, about 160 mm to 190 mm. However, this is not limiting, and for example, the length may be set to be shorter than the length of the mask body 10 in the left-right direction.

[0034] The length of the first base material 21 in the vertical direction is set to be approximately the same as the length of the mask body 10 in the vertical direction, and may be set to, for example, about 80 mm to 110 mm. However, this is not limiting, and for example, the length may be set to be shorter than the length of the mask body 10 in the vertical direction.

[0035] The thickness of the first base material 21 is set to a thickness that provides a desired durability, and may be set to, for example, about 0.03 mm to 0.5 mm.

[0036] The material of the first base material 21 is not limited, but in the present embodiment, the first base material 21 is made of a paper material, and specifically, the basis weight is 14 g / m 2 However, without being limited thereto, the mask may be made of a paper material other than the mask paper material (for example, tea-scented paper (specifically, tea-scented paper containing 20% ​​or more tea leaves) that has been confirmed to contribute to antiviral properties from the test results described below), or a cloth material for the mask (for example, a woven material, a nonwoven material, or a knitted material).

[0037] (Composition: Mask body, anti-viral layer) Returning to Fig. 1, the antiviral layer 22 is a layer for exerting the antiviral properties of the mask body 10. This antiviral layer 22 is formed by applying a tea leaf extract to the first substrate 21, and specifically, as shown in Figs. 1 and 2, the tea leaf extract is applied to substantially the entire first substrate 21 to be impregnated therein, and then dried to form the antiviral layer.

[0038] The specific configuration of the antiviral layer 22 is arbitrary, but in the embodiment, based on the test results described later, the coating amount of the tea leaf extract substance in the antiviral layer 22 is set to 0.1 g / m 2 The above is configured.

[0039] Specifically, from the viewpoint of ensuring a relatively high antiviral activity, the coating amount is set to 0.2 g / m based on the test results described later. 2 However, the present invention is not limited to this, and the coating amount is, for example, 0.2 g / m2 For example, the coating amount may be greater than 0.4 g / m 2 It may be configured so that:

[0040] The coating amount is 0.4 g / m 2 If the amount exceeds this amount, it becomes difficult to apply the tea leaf extract to the first substrate 21, and therefore it becomes difficult to form the antiviral layer 22 on the first substrate 21. In light of this, in the embodiment, the upper limit of the amount of application is set to 0.4 g / m 2 is set to a certain extent.

[0041] (Composition: Mask body, anti-viral layer, tea leaf extract) Here, the tea leaf extract is a substance extracted from tea leaves (for example, green tea leaves, black tea leaves, etc.).

[0042] The specific composition of the tea leaf extract is arbitrary, but in the embodiment, from the viewpoint of ensuring the quality of the mask body 10 (specifically, the quality related to antiviral properties), it contains catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate, and theaflavin-3,3'-digallate. However, it is not limited thereto, and may further contain, for example, other polyphenols (for example, gallocatechin and gallocatechin gallate) other than these.

[0043] In addition, the amount of tea leaf extract applied was 0.2 g / m 2 In this case, the amount of application of the components of the tea leaf extract, including catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate, and theaflavin-3,3'-digallate, is arbitrary, but in the embodiment, it is 0.1 g / m 2 However, it is not limited to this, and can be set to, for example, 0.1 g / m 2 Alternatively, it may be set to less than 0.1 g / m 2may be set to be greater than

[0044] Such an antiviral layer 22 can reliably exert the desired antiviral properties of the mask body 10. In addition, since the antiviral layer 22 can be formed from a tea leaf extract, the antiviral layer 22 can be easily formed, and since the antiviral layer 22 can be formed using, for example, used tea leaves, it is possible to contribute to the recycling of tea leaves while improving the manufacturability of the antiviral layer 22 (specifically, reducing the manufacturing cost, etc.).

[0045] (Configuration - Mask body - Outer second substrate) Returning to Fig. 1, the outer second substrate 23 is another part of the basic structure of the mask body 10, and is a substrate (second substrate) on which the antiviral layer 22 is not provided. The outer second substrate 23 is formed of a substantially sheet-like body, and is provided on the outer side of the first substrate 21 (on the front side in Fig. 1(b)) as shown in Fig. 1.

[0046] Further, the specific shape and size of the outer second base material 23 are arbitrary, but in the embodiment, they are set as follows.

[0047] That is, the front shape of the outer second base material 23 is set to a substantially quadrangular shape (specifically, a substantially rectangular shape). However, it is not limited to this, and may be set to, for example, a substantially square shape, a substantially trapezoidal shape, or a substantially elliptical shape.

[0048] The length of the second outer base material 23 in the left-right direction is set to be substantially the same as the length of the mask body 10 in the left-right direction, and may be set to, for example, about 120 mm to 190 mm.

[0049] The length of the second outer base material 23 in the up-down direction is set to be substantially the same as the length of the mask body 10 in the up-down direction, and may be set to, for example, about 80 mm to 110 mm.

[0050] The thickness of the outer second base material 23 is set to a thickness that provides a desired durability, and may be set to, for example, about 0.1 mm to 0.7 mm.

[0051] The material of the outer second base material 23 is not limited, but in the embodiment, it is made of a cloth material, specifically, a fabric weight of 25 g / m 2 The mask is made of a nonwoven material for a mask (for example, a spunbond nonwoven material, etc.). However, the mask is not limited to this, and may be made of a cloth material other than the nonwoven material for a mask (for example, a woven material or a knitted material), or a paper mask material.

[0052] (Configuration - Mask body - Inner second base material) The inner second substrate 24 is another part of the basic structure of the mask body 10, and is a substrate (second substrate) that is not provided with the antiviral layer 22. The inner second substrate 24 is formed of a substantially sheet-like body, and is provided on the inner side of the first substrate 21 (on the rear side in FIG. 1(b)), as shown in FIG. 1(b).

[0053] Further, the specific shape and size of the inner second base material 24 are arbitrary, but in this embodiment, they are set as follows.

[0054] That is, the front shape of the inner second base material 24 is set to be substantially quadrangular (specifically, substantially rectangular). However, it is not limited thereto, and may be set to be, for example, substantially square, substantially trapezoidal, or substantially elliptical.

[0055] The length of the second inner base material 24 in the left-right direction is set to be approximately the same as the length of the mask body 10 in the left-right direction, and may be set to, for example, about 160 mm to 190 mm. However, this is not limited thereto, and for example, the length may be set to be shorter than the length of the mask body 10 in the left-right direction.

[0056] The vertical length of the second inner base material 24 is set to be approximately the same as the vertical length of the mask body 10, and may be set to, for example, about 80 mm to 110 mm. However, this is not limiting, and for example, the length may be set to be shorter than the vertical length of the mask body 10.

[0057] The thickness of the inner second base material 24 is set to a thickness that provides a desired durability, and may be set to, for example, about 0.1 mm to 0.7 mm.

[0058] The material of the inner second base material 24 is not limited, but in the present embodiment, it is made of a cloth material, specifically, a material having a basis weight of 25 g / m 2 The mask is made of a nonwoven material for a mask (for example, a spunbond nonwoven material, etc.). However, the mask is not limited to this, and may be made of a cloth material other than the nonwoven material for a mask (for example, a woven material or a knitted material), or a paper mask material.

[0059] (Configuration - Mask body - Intermediate second substrate) The intermediate second substrate 25 is another part of the basic structure of the mask body 10, and is a substrate (second substrate) on which the antiviral layer 22 is not provided. The intermediate second substrate 25 is formed in a substantially sheet-like shape, and is provided between the first substrate 21 and the inner second substrate 24, as shown in FIG. 1(b).

[0060] Further, the specific shape and size of the intermediate second base material 25 are arbitrary, but in the embodiment, they are set as follows.

[0061] That is, the front shape of the intermediate second base material 25 is set to be substantially quadrangular (specifically, substantially rectangular). However, it is not limited thereto, and may be set to be, for example, substantially square, substantially trapezoidal, or substantially elliptical.

[0062] The length of the intermediate second base material 25 in the left-right direction is set to be approximately the same as the length of the mask body 10 in the left-right direction, and may be set to, for example, about 160 mm to 190 mm. However, this is not limited thereto, and for example, the length may be set to be shorter than the length of the mask body 10 in the left-right direction.

[0063] The vertical length of the intermediate second base material 25 is set to be approximately the same as the vertical length of the mask body 10, and may be set to, for example, about 80 mm to 110 mm. However, this is not limiting, and for example, the length may be set to be shorter than the vertical length of the mask body 10.

[0064] The thickness of the intermediate second base material 25 is set to a thickness that provides a desired durability, and may be set to, for example, about 0.1 mm to 0.7 mm.

[0065] The material of the intermediate second base material 25 is not limited, but in the present embodiment, the intermediate second base material 25 is made of a cloth material, specifically, a fabric weight of 25 g / m 2 For example, the fabric is made of a nonwoven material for masks with a basis weight of 25 g / m 2 By being made of a melt-blown material that has been subjected to an electrostatic treatment (corona treatment, for example), viruses that have passed through the first substrate 21 can be held by the intermediate second substrate 25, and the antiviral properties of the first substrate 21 can be exerted on the held viruses. However, without being limited thereto, for example, the mask may be made of a cloth material other than a nonwoven mask material (woven cloth material, knitted cloth material, for example), or a mask paper material.

[0066] (Configuration - Mask body - Other configurations) The specific configuration of the mask body 10 is arbitrary, but in this embodiment, it is configured as follows.

[0067] That is, first, a plurality of second substrates (specifically, an outer second substrate 23, an inner second substrate 24, and an intermediate second substrate 25) are arranged in a layered configuration, and the first substrate 21 is arranged between the second substrates so that the first substrate 21 is not exposed from the outside.

[0068] Specifically, as shown in Fig. 1(b), the outer second substrate 23, the inner second substrate 24, and the intermediate second substrate 25 are arranged in a layered manner approximately along the front-rear direction. The first substrate 21 is arranged between the outer second substrate 23 and the intermediate second substrate 25, and the entire front surface of the first substrate 21 is covered by the outer second substrate 23, and the entire rear surface of the first substrate 21 is covered by the inner second substrate 24 and / or the intermediate second substrate 25. The outer second substrate 23 and the intermediate second substrate 25 are connected to each other by ultrasonic bonding, thermal bonding, or adhesive (e.g., hot melt), and the intermediate second substrate 25 and the inner second substrate 24 are connected to each other by ultrasonic bonding, thermal bonding, or adhesive (e.g., hot melt), and the like.

[0069] With such a configuration, it is possible to prevent the first base material 21 from being exposed to the outside, and to prevent the first base material 21 from degrading the design of the mask body 10 (antiviral base material 20).

[0070] Furthermore, the mesh size of at least one of the second substrates located on one side of the first substrate 21 in the stacking direction is set to be smaller than the mesh size of the second substrate located on the other side of the first substrate 21 in the stacking direction.

[0071] Specifically, the size of the holes of at least one of the inner second substrate 24 and the intermediate second substrate 25, which are located behind the first substrate 21, is set to be smaller than the size of the holes of the outer second substrate 23, which is located in front of the first substrate 21. For example, the size of the holes of the intermediate second substrate 25 may be set to 10 μm or less, and the sizes of the holes of the outer second substrate 23 and the inner second substrate 24 may be set to 50 μm or more.

[0072] With this configuration, foreign matter and / or viruses are less likely to pass through compared to when the mesh sizes of the multiple second base materials are all the same, thereby improving the filtering function of the mask body 10. In particular, by setting the mesh sizes of the multiple second base materials to the above sizes, it becomes possible to apply the mask body 10 to a surgical mask.

[0073] The size of the holes in the first substrate 21 is arbitrary, but in the embodiment, it is set to a size between the size of the holes in the outer second substrate 23 and the size of the holes in the intermediate second substrate 25, and may be set to, for example, about 20 μm to 30 μm. However, it is not limited to this, and may be set to, for example, the same size as either the size of the holes in the outer second substrate 23 or the size of the holes in the intermediate second substrate 25.

[0074] Such a mask body 10 (antiviral substrate 20) can have the desired antiviral properties, and the quality of the mask body 10 can be ensured.

[0075] (Structure - Pleated section) Next, the configuration of the pleated portion 30 will be described.

[0076] The pleats 30 are provided to configure the mask body 10 three-dimensionally so that the mask body 10 fits the face of the wearer. The pleats 30 are formed by forming parts of the mask body 10 (specifically, the first base material 21, the outer second base material 23, the inner second base material 24, and the intermediate second base material 25) into elongated folds, and are arranged in parallel in the mask body 10 at intervals in the up-down direction, as shown in FIG.

[0077] (Configuration - Nose fitter section) Next, the configuration of the nose fitter portion 40 will be described.

[0078] The nose fitter portion 40 is for fitting the mask body 10 to the nose of the wearer. The nose fitter portion 40 is formed, for example, using a long, well-known nose fitter for masks (for example, a nose fitter made of polyolefin and iron), and as shown in Fig. 1, the longitudinal direction of the nose fitter portion 40 is provided at the upper end of the second outer base material 23 so as to be substantially aligned with the left-right direction, and is fixed to the second outer base material 23 by ultrasonic bonding, thermal bonding, adhesive (for example, hot melt), or the like.

[0079] (Configuration - Ear side detachable part) Next, the configuration of the ear-side detachable part 50 will be described.

[0080] The ear side attachment / detachment section 50 is an ear side attachment / detachment means for attaching the mask body 10 to the wearer's ears in a freely detachable manner, and as shown in FIG. 1, it has a first ear side attachment / detachment section 51 and a second ear side attachment / detachment section 52.

[0081] (Configuration - Ear side detachable part - First ear side detachable part) The first ear-side detachable part 51 is for attaching the mask body 10 to the right ear of the wearer in a detachable manner. The first ear-side detachable part 51 is made of, for example, a known ear-hanging string material (for example, a polyolefin string material in a substantially loop shape having a length that can be hung around the right ear), and is provided at the right end of the mask body 10. Specifically, as shown in FIG. 1, one end of the first ear-side detachable part 51 is connected to the upper part of the right end of the mask body 10 by ultrasonic bonding, thermal bonding, adhesive (for example, hot melt), etc., and the other end of the first ear-side detachable part 51 is connected to the lower part of the right end of the mask body 10 by ultrasonic bonding, thermal bonding, adhesive, etc.

[0082] (Configuration - Ear side detachable part - Second ear side detachable part) The second ear-side detachable part 52 is for attaching the mask body 10 to the left ear of the wearer in a detachable manner. The second ear-side detachable part 52 is made of, for example, a known ear-hanging string material (for example, a polyolefin string material in a substantially loop shape having a length that can be hung around the left ear) and is provided at the left end of the mask body 10. Specifically, as shown in FIG. 1, one end of the second ear-side detachable part 52 is connected to the upper part of the left end of the mask body 10 by ultrasonic bonding, heat bonding, adhesive, or the like, and the other end of the second ear-side detachable part 52 is connected to the lower part of the left end of the mask body 10 by ultrasonic bonding, heat bonding, adhesive, or the like.

[0083] With the mask 1 as described above, the quality of the mask body 10 can be ensured by the quality of the antiviral substrate 20, and the manufacturability of the mask 1 can be improved.

[0084] (Mask manufacturing method) Next, a method for manufacturing the mask 1 will be described.

[0085] The method for manufacturing the mask 1 according to the embodiment includes a first forming step, a second forming step, and an attaching step.

[0086] (Mask manufacturing method - first formation process) First, the first forming step will be described. The first formation step is a step for forming the antiviral layer 22 on the first substrate 21.

[0087] Specifically, while the roll-shaped first substrate 21 is being unwound by a known unwinder, a coating liquid is applied to the mask outer surface 12 of the unwound first substrate 21 using known coater equipment (e.g., a gravure coater). Then, the coated first substrate 21 is dried for a predetermined time by known drying equipment (e.g., a hot air dryer, etc.), thereby forming the antiviral layer 22. Thereafter, the first substrate 21 on which the antiviral layer 22 has been formed is cut to a predetermined size by a known cutting machine.

[0088] Here, the "coating liquid" refers to a liquid for coating the tea leaf extract on first substrate 21, and contains, for example, tea leaf extract, water, ethanol, isopropyl alcohol, and the like.

[0089] The amount of the coating liquid applied to the first substrate 21 is arbitrary, but in this embodiment, the amount of the tea leaf extract applied is 0.2 g / m 2 For example, the coating amount of the coating liquid is set to 0.8 g / m 2 It may be set to a certain extent.

[0090] (Mask manufacturing method - second formation process) Next, the second forming step will be described. The second forming step is a step for forming the mask body 10 after the first forming step.

[0091] Specifically, first, the outer second substrate 23, the inner second substrate 24, and the intermediate second substrate 25 are provided in a layered manner by a known processing device or the like, and the first substrate 21 is disposed between the outer second substrate 23 and the intermediate second substrate 25. Next, the outer second substrate 23, the inner second substrate 24, the intermediate second substrate 25, and the first substrate 21 disposed as described above are pleated by a known processing device, thereby forming the pleat portion 30. Thereafter, the outer second substrate 23 and the intermediate second substrate 25 are mutually connected by ultrasonic bonding or the like, and the intermediate second substrate 25 and the inner second substrate 24 are mutually connected by ultrasonic bonding or the like, by a known bonding device, thereby forming the mask body 10.

[0092] (Mask manufacturing method - mounting process) Next, the attachment step will be described. The attachment step is a step for attaching the nose fitter portion 40 and the ear-side detachable portion 50 to the mask body 10 after the second forming step.

[0093] Specifically, the nose fitter part 40 is attached to the mask body 10 by connecting the nose fitter part 40 to the mask body 10 (specifically, the second outer base material 23) by ultrasonic bonding or the like using a known attachment device. Also, the ear side detachable part 50 is attached to the mask body 10 by connecting the ear side detachable part 50 to the mask body 10 by ultrasonic bonding or the like using a known sewing device.

[0094] By using such a manufacturing method, the mask 1 can be easily manufactured. Furthermore, in the first forming step, the amount of tea leaf extract applied is 0.2 g / m 2 Since the antiviral layer 22 can be formed by applying the coating liquid to the first substrate 21 so as to achieve the above-described structure, the mask body 10 can have the desired antiviral properties, and the quality of the mask body 10 can be ensured.

[0095] (Test Results) Next, the results of the first to fifth antiviral confirmation tests conducted by the applicant will be described.

[0096] (Test results - Summary of the first antiviral confirmation test) First, an overview of the first antiviral confirmation test will be described. Here, the "first antiviral confirmation test" is a test for confirming whether or not each test specimen has antiviral properties against the avian influenza virus.

[0097] The test method for the first antiviral confirmation test was optional, but was carried out as follows. First, 0.2 g of each test specimen was diluted with a virus liquid containing avian influenza virus (specifically, 10 mL of PBS (phosphate buffered saline)). 9.5 EID 50400μl of virus solution (adjusted to 0.2ml / ml) was applied and reacted at room temperature for 10 minutes. Next, the reaction solution extracted from each test specimen was serially diluted 10-fold with PBS containing antibiotics, and 0.2ml was inoculated into the chorioallantoic membrane of an embryonated chicken egg, followed by culturing for 2 days. Next, allantoic fluid was collected from each embryonated chicken egg chorioallantoic membrane, and the proliferation status of the virus in the collected allantoic fluid was detected using the HA test. The results of the detection were then recorded as virus titers (log 10 EID 50 / 0.2 ml) (Note that FIG. 3 shows the average viral titer calculated based on the results of multiple detections).

[0098] The test specimens used in the first antiviral confirmation test are divided into test specimens A1 to A5.

[0099] Here, the test specimen A1 is tea-scented paper containing used tea leaves (specifically, tea-scented paper containing 20% ​​used tea leaves in pulp paper). The test specimen A2 is the above-mentioned tea-scented paper with an antiviral layer 22 (specifically, the amount of tea leaf extract applied is 0.1 g / m 2 The test specimen A3 is the one in which the antiviral layer 22 (specifically, the coating amount of the tea leaf extract is 0.2 g / m2) is formed on the tea scented paper. 2 The specimen A4 is a tea scented paper containing used tea leaves (specifically, a tea scented paper containing 60% used tea leaves relative to the paper material). The specimen A5 is a simple pulp paper.

[0100] (Test results - details of the first antiviral confirmation test) Next, the test results of the first antiviral confirmation test will be described in detail.

[0101] As shown in Figure 3, it was confirmed that the virus titers of the test specimens A1 to A4 were lower than that of the test specimen A5. In particular, it was confirmed that the virus titers of the test specimens A2 and A3 were lower than that of the test specimens A1 and A5.

[0102] In addition, regarding the antiviral activity value (a value for determining the presence or absence of antiviral properties, which is the value obtained by subtracting the viral titer of test specimen A5 from the viral titer of each test specimen), although the antiviral activity values ​​of test specimen A1 and test specimen A4 did not meet the standard value (≧2.0 (standard value defined in ISO 18184)) (indicated by "x" in Figure 3), it was confirmed that the antiviral activity values ​​of test specimen A2 and test specimen A3 met the standard value (indicated by "o" in Figure 3). Therefore, it was confirmed that test specimen A1 and test specimen A4 did not have the desired antiviral properties, and that test specimen A2 and test specimen A3 had the desired antiviral properties.

[0103] In addition, it was confirmed that the corrected antiviral activity values ​​(values ​​for determining the presence or absence of antiviral properties, obtained by subtracting the antiviral activity value of test specimen A1 from the antiviral activity value of test specimen A2 or test specimen A3) of test specimen A2 and test specimen A3 satisfied the above-mentioned standard value (indicated by "(◯)" in FIG. 3). In particular, it was confirmed that the corrected antiviral activity value of test specimen A3 also satisfied the standard value (≧3.0, hereinafter referred to as the "high standard value") indicating a higher antiviral activity as stipulated in ISO 18184. Therefore, it was confirmed that the antiviral layer 22 of test specimen A2 and test specimen A3 had the desired antiviral properties.

[0104] From the above, the application amount of the tea leaf extract in the antiviral layer 22 is set to 0.1 g / m 2 The effectiveness of the above was confirmed. In addition, the effectiveness of the combination of forming the antiviral layer 22 and the first base material 21 from tea-scented paper was also confirmed.

[0105] (Test results - Summary of the second antiviral confirmation test) Next, an overview of the second antiviral confirmation test will be described. Here, the "second antiviral confirmation test" is a test for confirming whether or not each test specimen has antiviral properties against coronavirus (delta strain).

[0106] The second antiviral confirmation test was carried out in any manner, but was carried out as follows. That is, host cells were infected with coronavirus, EMEM was added and the cells were cultured for a predetermined period of time, and then the cells were centrifuged at 4°C and 1000×g for 15 minutes in a centrifuge to obtain a virus suspension. Next, the virus suspension was diluted 10-fold with sterilized distilled water to obtain a virus suspension of 1 to 5×10 7 The test virus suspension was adjusted to PFU / ml. Then, 0.2 ml of the test virus suspension was inoculated onto each 0.4 g test specimen. Next, each test specimen was allowed to act at 25°C for 2 hours, and then each test specimen to which 20 ml of washing solution had been added was stirred in a box mixer. Next, the coronavirus was washed out from each of the stirred test specimens, and the virus titer was determined by the Braak method (note that Figure 4 shows the average virus titer calculated based on the results of multiple detections).

[0107] The test specimens used in the second antiviral confirmation test are divided into test specimens B1 and B2.

[0108] Here, the test specimen B1 is a simple pulp paper. The test specimen B2 is a simple pulp paper with an antiviral layer 22 (specifically, the amount of tea leaf extract applied is 0.2 g / m 2 An antiviral layer 22) is formed.

[0109] (Test results - Details of the second antiviral confirmation test) Next, the details of the test results of the second antiviral confirmation test will be described.

[0110] As shown in FIG. 4, it was confirmed that the virus titer of the test sample B2 was lower than that of the test sample B1.

[0111] In addition, regarding the antiviral activity value (a value for determining the presence or absence of antiviral properties, which is the value obtained by subtracting the viral titer of test specimen B1 from the viral titer of each test specimen), it was confirmed that the antiviral activity value of test specimen B2 satisfied the above-mentioned standard value (indicated by "◯" in FIG. 4), and also satisfied the above-mentioned high standard value. Therefore, it was confirmed that test specimen B2 has the desired antiviral properties.

[0112] From the above, the application amount of the tea leaf extract in the antiviral layer 22 is set to 0.2 g / m 2 The effectiveness of this approach was confirmed.

[0113] (Test results - Summary of the 3rd antiviral confirmation test) Next, an overview of the third antiviral confirmation test will be described. Here, the "third antiviral confirmation test" is a test for confirming whether or not each test specimen has antiviral properties against influenza virus (type A).

[0114] The test method for the third antiviral confirmation test was optional, but was performed as follows. That is, first, 400 mg of each test specimen and 0.2 ml of influenza virus solution prepared using 10% Eagle medium-containing water were placed in a centrifuge tube and left to stand for 2 hours at 37°C and 5% CO2. Next, the influenza virus solution was extracted from the centrifuge tube using 20 ml of SCDLP medium, and a 10-fold serial dilution system was prepared using the extracted influenza virus solution. Next, 1 ml of the 10-fold serial dilution system was dropped onto host cells, and infection treatment was performed for 1 hour at 37°C and 5% CO2. Next, the infected cell supernatant was replaced with a 0.8% oxoid agar solution, and cultured for 1-2 days at 37°C and 5% CO2. Next, the formation of Braak was visually confirmed, and then the cultured product was fixed with a 5% glutaraldehyde solution and stained with methylene blue. Then, the virus titer was determined based on the measurement data of the number of Braaks formed.

[0115] In addition, the test specimens used in the third antiviral confirmation test are divided into test specimens C1 to C3.

[0116] Here, the test specimen C1 is tea scented paper (specifically, tea scented paper containing 20% ​​tea leaves in pulp paper). The test specimen C2 is a simple pulp paper with an antiviral layer 22 (specifically, the amount of tea leaf extract applied is 0.2 g / m 2 The test specimen C3 is a simple nonwoven fabric material having an antiviral layer 22 (specifically, the amount of tea leaf extract applied is 0.2 g / m2). 2 An antiviral layer 22) is formed.

[0117] (Test results - details of the third antiviral confirmation test) Next, the details of the test results of the third antiviral confirmation test will be described.

[0118] As shown in FIG. 5, it was confirmed that the virus titers of the test specimens C2 and C3 were lower than that of the test specimen C1.

[0119] In addition, it was confirmed that the antiviral activity values ​​of test specimens C2 and C3 (values ​​for determining the presence or absence of antiviral properties, obtained by subtracting the viral titer of test specimen C1 from the viral titer of each test specimen) met the above-mentioned standard values ​​(indicated by "◯" in FIG. 5). Therefore, it was confirmed that test specimens C2 and C3 had the desired antiviral properties.

[0120] From the above, the application amount of the tea leaf extract in the antiviral layer 22 is set to 0.2 g / m 2 The effectiveness of this approach was confirmed.

[0121] (Test results - Summary of the 4th antiviral confirmation test) Next, an outline of the fourth antiviral confirmation test will be described. Here, the "fourth antiviral confirmation test" is a test for confirming the presence or absence of antiviral properties of each test specimen against coronavirus (delta strain), similar to the second antiviral confirmation test.

[0122] In addition, the test method for the fourth antiviral confirmation test was optional, but was carried out in the same manner as the second antiviral confirmation test.

[0123] In addition, the test specimens used in the 4th antiviral confirmation test are divided into test specimens D1 and D2.

[0124] Here, the test specimen D1 is a simple pulp paper. The test specimen D2 is a simple pulp paper with an antiviral layer 22 (specifically, the amount of tea leaf extract applied is 0.4 g / m 2 An antiviral layer 22) is formed.

[0125] (Test results - details of the 4th antiviral confirmation test) Next, the details of the test results of the fourth antiviral confirmation test will be described.

[0126] As shown in FIG. 6, it was confirmed that the virus titer of the test sample D2 was lower than that of the test sample D1.

[0127] In addition, regarding the antiviral activity value (a value for determining the presence or absence of antiviral properties, which is the value obtained by subtracting the viral titer of test specimen D1 from the viral titer of each test specimen), it was confirmed that the antiviral activity value of test specimen D2 satisfied the above-mentioned standard value (indicated by "◯" in FIG. 6), and also satisfied the above-mentioned high standard value. Therefore, it was confirmed that test specimen D2 has the desired antiviral properties.

[0128] From the above, the application amount of the tea leaf extract in the antiviral layer 22 is set to 0.4 g / m 2 The effectiveness of this approach was confirmed.

[0129] (Test results - Summary of the 5th antiviral confirmation test) Next, an overview of the fifth antiviral confirmation test will be described. Here, the "fifth antiviral confirmation test" is a test for confirming whether or not each test specimen has antiviral properties against coronavirus (Omicron strain).

[0130] In addition, the test method for the fifth antiviral confirmation test was optional, but was carried out in the same manner as the second antiviral confirmation test.

[0131] In addition, the test specimens used in the 5th antiviral confirmation test are divided into test specimens E1 and E2.

[0132] Here, the test specimen E1 is a simple pulp paper. The test specimen E2 is a simple pulp paper with an antiviral layer 22 (specifically, the amount of tea leaf extract applied is 0.2 g / m 2 An antiviral layer 22) is formed.

[0133] (Test results - Details of the 5th antiviral confirmation test) Next, the details of the test results of the fifth antiviral confirmation test will be described.

[0134] As shown in FIG. 7, it was confirmed that the virus titer of the test specimen E2 was lower than that of the test specimen E1.

[0135] In addition, regarding the antiviral activity value (a value for determining the presence or absence of antiviral properties, which is the value obtained by subtracting the viral titer of test specimen E1 from the viral titer of each test specimen), it was confirmed that the antiviral activity value of test specimen E2 satisfied the above-mentioned standard value (indicated by "◯" in FIG. 7), and also satisfied the above-mentioned high standard value. Therefore, test specimen E2 was confirmed to have the desired antiviral properties.

[0136] From the above, the application amount of the tea leaf extract in the antiviral layer 22 is set to 0.2 g / m 2The effectiveness of this approach was confirmed.

[0137] (effect) Thus, according to the embodiment, the antiviral substrate 20 is provided with the antiviral layer 22 formed by applying a tea leaf extract extracted from tea leaves to the first substrate 21, and the amount of the tea leaf extract applied to the antiviral layer 22 is set to 0.1 g / m 2 As described above, it is possible to have a desired antiviral property, and it is possible to ensure the quality of the antiviral substrate 20 (specifically, the quality related to the antiviral property).

[0138] The amount of tea leaf extract applied to the antiviral layer 22 is set to 0.2 g / m 2 As described above, the antiviral base material can have a relatively high antiviral property, and the quality of the antiviral base material can be further ensured.

[0139] In addition, since the tea leaf extract contains catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate, and theaflavin-3,3'-digallate, it is possible to reliably have the desired antiviral properties, making it easier to ensure the quality of the antiviral base material 20.

[0140] Furthermore, multiple second substrates are provided in a layered configuration, and first substrate 21 is provided between adjacent second substrates so that first substrate 21 is not exposed from the outside. This makes it possible to avoid exposure of first substrate 21 from the outside, prevents the design of anti-viral substrate 20 from being reduced by first substrate 21, and enhances the protective properties of the first substrate.

[0141] Furthermore, the mesh size of at least one of the multiple second substrates located on one side of the first substrate 21 in the stacking direction is made smaller than the mesh size of the second substrate located on the other side of the first substrate 21 in the stacking direction. This makes it more difficult for foreign matter and / or viruses to pass through compared to when the mesh sizes of the multiple second substrates are all the same, thereby improving the filtering function.

[0142] In addition, since the mask 1 includes the mask body 10 made of the antiviral substrate 20, the quality of the mask body 10 can be ensured by the quality of the antiviral substrate 20, and the manufacturability of the mask 1 can be improved.

[0143] [III] Modifications to the embodiment Although the embodiments of the present invention have been described above, the specific configurations and means of the present invention can be modified and improved as desired within the scope of the technical ideas of the inventions described in the claims. Such modifications will be described below.

[0144] (About the problem to be solved and the effects of the invention) First, the problems that the invention aims to solve and the effects of the invention are not limited to those described above, and the present invention may solve problems that are not described above or achieve effects that are not described above, or may solve only some of the problems that are described or achieve only some of the effects that are described.

[0145] (shape, number, structure, time series) The components illustrated in the embodiments and drawings may be modified and improved as desired within the scope of the technical concept of the present invention with respect to the shape, numerical values, or structure or chronological relationships of multiple components.

[0146] (Applicable subjects of antiviral substrate) In the above embodiment, the antiviral substrate 20 is described as being applied to the mask 1 (specifically, the mask body 10), but it is not limited thereto, and may be applied, for example, to paper products and / or cloth products other than the mask 1. In this case, the first substrate 21 and / or the second substrate may be formed of paper material (for example, packaging paper material, printing paper material, cushioning paper material, paper container paper material, etc.) and / or cloth material (for example, woven fabric material, nonwoven fabric material, knitted fabric material, etc.).

[0147] (About masks) In the above embodiment, the mask 1 has been described as including the pleat portion 30 and the nose fitter portion 40, but this is not limiting, and for example, the pleat portion 30 and / or the nose fitter portion 40 may be omitted.

[0148] (About antiviral substrate) In the above embodiment, the antiviral substrate 20 is described as having a plurality of second substrates (the outer second substrate 23, the inner second substrate 24, and the intermediate second substrate 25), but this is not limited thereto. For example, in addition to the plurality of second substrates, another second substrate may be further provided. Alternatively, at least one of the plurality of second substrates may be omitted. As an example, the intermediate second substrate 25 may be omitted, or the outer second substrate 23, the inner second substrate 24, and the intermediate second substrate 25 may be omitted.

[0149] (Regarding the first substrate) In the above embodiment, the first base material 21 is provided between the second base materials so as not to be exposed to the outside, but this is not limiting. For example, the first base material 21 may be provided so as to be exposed to the outside.

[0150] (About the antiviral layer) In the above embodiment, it has been described that the anti-viral layer 22 is formed by applying the tea leaf extract to substantially the entire first substrate 21, but this is not limited thereto. For example, the anti-viral layer 22 may be formed by applying the tea leaf extract to only a portion of the first substrate 21 (for example, a portion other than the end of the first substrate 21).

[0151] (Regarding the second substrate) In the above embodiment, it has been described that the mesh size of the intermediate second substrate 25 located on one side of the first substrate 21 in the stacking direction among the multiple second substrates is set to be smaller than the mesh size of the outer second substrate 23 located on the other side of the first substrate 21 in the stacking direction, but this is not limited thereto. For example, the mesh size of each of the inner second substrate 24 and the intermediate second substrate 25 located on one side of the first substrate 21 in the stacking direction may be set to be smaller than the mesh size of the outer second substrate 23. Alternatively, the mesh sizes of all of the multiple second substrates may be set to be approximately the same.

[0152] (Additional Note) The antiviral substrate of Appendix 1 is an antiviral substrate having antiviral properties, and includes a first substrate made of a paper material or a cloth material, and an antiviral layer formed by applying a tea leaf extract extracted from tea leaves to the first substrate, and the amount of the tea leaf extract applied to the antiviral layer is 0.1 g / m 2 That's all.

[0153] The antiviral substrate of Appendix 2 is the antiviral substrate of Appendix 1, wherein the coating amount of the tea leaf extract in the antiviral layer is 0.2 g / m 2 That's all.

[0154] The antiviral substrate of Appendix 3 is the antiviral substrate of Appendix 1 or 2, wherein the tea leaf extract comprises catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate, and theaflavin-3,3'-digallate.

[0155] The antiviral substrate of Appendix 4 is the antiviral substrate according to any one of Appendix 1 to 3, which comprises a plurality of second substrates made of a paper material and / or a cloth material, the plurality of second substrates not provided with the antiviral layer, the plurality of second substrates being provided in a layered configuration, and the first substrates being provided between the second substrates so that the first substrates are not exposed from the outside.

[0156] The antiviral substrate of Supplementary Note 5 is the antiviral substrate of Supplementary Note 4, wherein the mesh size of at least one of the second substrates located on one side of the first substrate in the stacking direction is smaller than the mesh size of the second substrate located on the other side of the first substrate in the stacking direction.

[0157] The mask of Supplementary Note 6 comprises a mask body made of the antiviral substrate of any one of Supplementary Notes 1 to 5.

[0158] (Effect of supplementary notes) According to the antiviral base material described in Appendix 1, an antiviral layer is provided by applying a tea leaf extract extracted from tea leaves to a first base material, and the amount of the tea leaf extract applied to the antiviral layer is 0.1 g / m 2 As described above, it is possible to have a desired antiviral property, and ensure the quality of the antiviral base material (specifically, the quality related to the antiviral property).

[0159] According to the antiviral base material described in Appendix 2, the coating amount of the tea leaf extract in the antiviral layer is 0.2 g / m 2 As described above, the antiviral base material can have a relatively high antiviral property, and the quality of the antiviral base material can be further ensured.

[0160] According to the antiviral base material described in Appendix 3, the tea leaf extract contains catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate, and theaflavin-3,3'-digallate, so that the desired antiviral properties can be reliably obtained and the quality of the antiviral base material can be easily ensured.

[0161] According to the antiviral substrate described in Appendix 4, a plurality of second substrates are provided in a layered configuration, and the first substrates are provided between the second substrates so that the first substrates are not exposed from the outside. This makes it possible to prevent the first substrate from being exposed from the outside, prevent a decrease in the design of the antiviral substrate due to the first substrate, and enhance the protective properties of the first substrate.

[0162] According to the anti-viral substrate described in Appendix 5, the mesh size of at least one of the second substrates located on one side of the first substrate in the stacking direction is smaller than the mesh size of the second substrate located on the other side of the first substrate in the stacking direction. This makes it more difficult for foreign matter and / or viruses to pass through compared to a case in which the mesh sizes of the multiple second substrates are all the same, thereby improving the filtering function.

[0163] The mask described in Supplementary Note 6 includes a mask body made of the antiviral substrate according to any one of Supplementary Notes 1 to 5. Therefore, the quality of the mask body can be ensured by the quality of the antiviral substrate, and the manufacturability of the mask can be improved. [Explanation of symbols]

[0164] 1. Mask 10 Mask body 11 Inside of the mask 12 Mask outer surface 20 Antiviral Substance 21 First base material 22 Antiviral Layer 23 Second outer base material 24 Inner second base material 25 Intermediate second substrate 30 Pleats 40 Nose fitter section 50 Ear side detachable part 51 First ear side attachment part 52 Second ear side attachment part

Claims

1. An antiviral substrate having antiviral properties, A first substrate made of a paper material or a cloth material; an antiviral layer provided on the first base material, the antiviral layer containing a substance including catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate, and theaflavin-3,3'-digallate; a plurality of second substrates made of paper and / or cloth, the second substrates not being provided with the antiviral layer; The amount of the substance contained in the antiviral layer is set to 0.2 g / m ２ to 0.4 g / m ２ year, The plurality of second base materials are provided in a laminated state, The first base material is provided between the second base materials so that the first base material is not exposed to the outside; the plurality of second base materials include an outer second base material located on one side of the first base material in the stacking direction, an inner second base material located on the other side of the first base material in the stacking direction, and an intermediate second base material located between the first base material and the inner second base material, The size of the holes of at least one of the inner second substrate or the intermediate second substrate is made smaller than the size of the holes of the outer second substrate; The size of the holes in the first substrate is the same as the size of the holes in the intermediate second substrate. Antiviral substrate.

2. the amount of components including catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate, and theaflavin-3,3'-digallate among the components of the substance is about half of the amount of the substance contained in the antiviral layer; The antiviral substrate according to claim 1.

3. A mask having a mask body made of the antiviral substrate described in claim 1 or 2.

Images